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Abstract
Aim: Elevated levels of sterol regulatory element-binding protein-1 (SREBP-1) have been found in endometrial cancer (EC),
suggesting that it is essential to the development of EC. Obesity and diabetes have been established as known risk factors
of EC, while SREBF-1 gene polymorphisms have also been found to be associated with obesity and type II diabetes.
Therefore, we hypothesize that single nucleotide polymorphism (SNP) in SREBF-1 gene may be associated with increased
risk of EC.
Method: We analyzed the sequence of SREBF-1 in tissue samples from 30 EC cases and 6 benign controls using high
throughput method. Based on the primary results, we selected one SNP (rs2297508) as a genetic marker to conduct a
hospital-based case-control study with 139 EC cases and 129 benign controls. The samples were examined under the
microscope to determine their histopathology prior to the SNP analysis using RT-PCR.
Results: Through sequence analysis, we found 10 SNPs of SREBF-1 associated with EC, including 3 new SNPs. Fourteen
percent of EC showed the rs2297508 SNP with C allele, while only 7% had the C allele was present in benign controls
(p = 0.027, OR = 1.983). Additionally, the C allele was associated with cancer differentiation (p,0.05) and the depth of
myometrial invasion (p,0.05).
Conclusion: Our study indicates that SNP (rs2297508) of SREBF-1 may serve as a genetic predisposition factor for the
development of EC and screening of such genetic marker may be helpful in its early detection.
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Sterol regulatory element-binding proteins (SREBPs) are
transcription factors of the helix-loop-helix–leucine zipper
(HLH-LZ) family. Three isoforms of SREBP have been identified
in mammalian cells: SREBP-1a, SREBP-1c and SREBP-2 [7].
Two genes(SREBF-1 and SREBF-2) are responsible for expressing
these proteins of which SREBF-1 gene is located on chromosome
17 p11.2. There is an overlap in the pathways and functions
among the individual SREBPs, but most studies suggest that
SREBP-1 mainly regulates fatty acid metabolism and SREBP-2 is
the main regulator of cholesterol metabolism [8]. SREBP-1
regulates lipid homeostasis by controlling the expression of the key
rate-limiting enzymes required for cholesterol and fatty acid
synthesis [9]. Aberrant lipogenesis is an important metabolic
feature involved in rapid proliferation of the malignant tumor
cells. Several studies have shown that tumor cells are capable of
reactivating de novo lipid synthesis and expressing elevated levels

Introduction
Endometrial cancer (EC) is the most common gynecological
malignancy in the western world and the fourth most common
cancer in women. The incidence of the EC has increased by 21%
since 2008, and the mortality rate has increased significantly over
the past two decades [1]. The American Cancer Society estimated
49,500 new cases and 8,200 mortalities in 2013 [2]. The etiology
of EC is multifactorial and involves increased exposure to estrogen
[3] and genetic risk factors. So far, it has been proven that several
SNPs are associated with an increased risk of EC, such as
nucleoside diphosphate kinase 1(nm23-H1;rs16949649 and
rs2302254), serpin peptidase inhibitor, clade E(PAI-1;rs1799889)
and progesterone receptor (PGR;rs11224561) [4–6]. To understand the genetic risk factors comprehensively and find effective
targets, it is necessary to identify the related SNPs.
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To our knowledge, no study to date has reported the potential
association of SREBF-1 genetic polymorphism with the risk of EC.
We hypothesize that SNPs in SREBF-1 might be associated with
increased risk of EC, along with several clinical criteria like
pathologic grade, clinical stage, pathologic type etc. The SNPs of
SREBF-1 may serve as genetic predisposition factors for the
development of EC and screening of such genetic markers could
be of great value for an earlier detection of this disease.

of fatty acid synthase (FASN) [10] which is regulated by SREBP-1
[11]. Consistent with these findings, SREBP-1 has been demonstrated to have an association with many other malignant tumors
such as breast cancer, prostate cancer and colorectal cancer as well
[12–15].
Through the mechanism of lipid biosynthesis, SREBP-1 has
been proposed to be a causative factor of obesity [16]. Obesity on
the other hand is considered responsible for various mechanisms
that precipitate into carcinogenesis [7]. Through the mechanism
of insulin resistance, obesity induces the secretion of insulin from
the pancreatic cells. Insulin in turn has a stimulatory effect on
SREBP1 [17]. Recently, higher level of SREBP-1 has been
detected in EC cells compared to the normal endometrium, and
which was more prominent in higher-grade EC. Additionally,
knockdown of SREBP1 was found to effectively repress the
proliferating capacity of EC cells and tumor growth in vitro,
further indicating that SREBP-1 plays an important role in the
progression of EC [18].

Materials and Methods
Ethics statement
The endorsed written informed consents were acquired from all
the participants and the samples were collected with the approval
of the Ethics Committee at Qilu Hospital of Shandong University.
In our study, we conducted a case-control analysis with a total of
139 cases and 129 controls. We firstly screened the entire gene of
SREBF-1 in 30 unrelated EC patients and 6 controls to identify
the associated SNPs. Based on the results we obtained, we chose

Figure 1. A: SNPs in SREBF-1 gene. The whole SREBF-1gene includes 22 exons. Ten SNPs (SNP1 to SNP10) were identified within the SREBF-1 in our
study. FIG. 1 B: SNP ID. SNP1 to SNP10 are listed from 59-39 of the SREBF-1. ‘‘CHR-ID’’ shows chromosome ID of ten SNPs in SREBF-1. Listed ‘‘RS ID’’ has
been reported in ucsc or NCBI website, ‘‘-’’ expresses newly detected SNP. ‘‘Function’’ column listed altered genetically coded function of the SNPs.
‘‘Ref SNP’’ shows SNP form in original reference sequence. In ‘‘mRNA location’’, corresponding mRNA positions are showed in consistent with each
SNP. (For details:Sequence IDs included in CCDS 32583.1). NCBI db is available from http://www.ncbi.nlm.nih.gov/SNP.
doi:10.1371/journal.pone.0090491.g001
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one SNP (rs2297508) which was found in eight out of the thirty
patients and none of the six controls and conducted a case-control
study in order to verify its association with EC.

30 sec at 94uC, 30 sec at 60uC,30 sec at 72uC and a 10-min final
extension at 72uC. The forward and reverse primers were 59
GACCTGAGGCTCCTGTGCTAC 39 and 59 AAGTCAGTCCATCCTCCCGT 39 respectively.

Study subjects
Selection of SREBF-1 polymorphism points

A total of 268 unbiased candidates were recruited stochastically.
The samples of 139 EC specimen and 129 benign controls were
collected based on their pathological reports. The endometrial
samples from 139 cancer patients were obtained through surgical
resection after hysterectomy performed at Qilu hospital Dept. of
gynecology. The tissue samples for controls were collected from
the patients with no fertility problems and with benign pathologies
like leiyomyomas, adenomyosis etc. The individual samples were
examined under the microscope for pathological diagnosis for both
groups. The EC patients were divided into two groups, 91 without
diabetes and obesity and 48 with diabetes and/or obesity and this
information was got from the hospital records. The normal
controls with diabetes or obesity (BMI§28 Kg/m2) were excluded
due to the possible association of SNP (rs2297508) with both of the
metabolic disorders as described in the study by Liu J. X.et al.[20].
Also, the controls had no known history of diabetes, obesity or any
other malignancies in their family. The mean age of 48 patients
with obesity and/or diabetes was 53.0966.7 and that of the 91
patients without diabetes or obesity was 54.3669.7(P = 0.196).
The mean age of the normal controls (52.4667.7) was comparable
to that of the 91 patients (P = 0.215). The EC patients were treated
surgically in Qilu Hospital from 2008 to 2012. They were
categorized into endometrioid (type I) and non-endometrioid (type
II) EC and the tumors were staged in accordance to the 2009
International Federation of Gynecology and Obstetrics (FIGO)
classification.

In order to access adequate information about the potential
association of SNPs in SREBF-1 with endometrial cancer, we first
screened the entire gene of SREBF-1 in 30 unrelated patients and
6 controls by high throughput sequencing technique using
PSTAR-II plus (IDN01-M-P2). The 36 subjects were randomly
chosen and matched on the basis of their ages. We were able to
identify 10 SNPs, including three newly detected ones. All the
findings were assayed by Pstar-II 6.0.4 build3 software. For the
association study, we selected only one SNP (rs2297508) based on
its allelic frequency which exhibited an obvious and significant
relation to EC.

SREBF-1 genotyping
Real-time polymerase chain reaction analysis was used to
genotype the SNP (rs2297508) in SREBF-1. The primer sequences
for the SNP were as follows: gF 59 CTCCCCCAGCACCTACGG
39, cF 59 CTCCCCCAGCACCTACGC 39 as the forward primer
and R 59 CTCCCCACTCCTCCCACTAAC 39 as the reverse
primer. The reaction system (20 ul) for rt-PCR included 10 ul AllIn-One qPCR Mix, 0.4 ul forward Primer F (2 mM), 0.4 ul reverse
Primer R (2 mM), 2 ul genomic DNA and 7.2 ul ddH2O. The
reaction procedure was conducted on a real time PCR
instrument(Step One Plus(ABI)) dividing into three stages: holding
stage at 95uC for 20 s, cycling stage of 40 cycles each including 3 s
at 95uC and then 30 s at 60uC, melting curve stage at 60uC for
60 s followed by 95uc for 15 s.

DNA preparation
The fresh tissue specimen collected was stored at 280uC
refrigeration. Genomic DNA was extracted from the tissues using
a QIAamp DNA Mini kit (Qiagen, USA) following the manufacturer’s protocol. The extracted DNA was dissolved in TE buffer
[10 mMTris (pH 7.8), 1 mM EDTA] and then the concentration
was measured with a reference to OD value of 260 nm (BIO-RAD
SmartSpec Plus). The final preparation was stored at 220uC for
PCR amplification. Amplifications was conducted using a 5 min
initial denaturation at 94uC, followed by 30 cycles each lasting

Statistical Analysis
Hardy–Weinberg equilibrium analyses were conducted to
compare genotype frequencies using x2 test among controls
(x2 = 1.24, p = 0.26). Comparison of genotype frequencies between
EC patients and controls were performed using Pearson x2 test.
We also evaluated the relationship between genotype distribution
of SREBF-1 SNPs and the clinical criteria of EC (divided on the
basis of presence or absence of diabetes and obesity, age,

Table 1. Genotypic and allelic frequencies of the 10 SNPs in the 6 controls and 30 EC patients.

Normal controls

EC patients

Genotype frequency(%)
1/1

Allele frequency(%)

Genotype frequency(%)

Allele frequency(%)

1/2

2/2

1

2

1/1

1/2

2/2

1

2

SNP1

C/T

83.3

16.7

0

91.7

8.3

93.3

6.7

0

96.7

3.3

SNP2

T/C

100

0

0

100

0

90.0

10.0

0

95.0

5.0

SNP3

C/G

100

0

0

100

0

96.7

3.3

0

98.3

1.7

SNP4

G/A

0

66.7

33.3

33.3

66.7

3.3

56.7

40.0

31.7

68.3

SNP5

T/C

100

0

0

100

0

93.4

3.3

3.3

90.0

10.0

SNP6

C/T

100

0

0

100

0

96.7

3.3

0

98.3

1.7

SNP7

T/G

100

0

0

100

0

96.7

3.3

0

98.3

1.7

SNP8

C/T

100

0

0

100

0

96.7

3.3

0

98.3

1.7

SNP9

G/C

100

0

0

100

0

73.3

20.0

6.7

83.3

16.7

SNP10

C/T

0

16.7

83.3

8.3

91.7

6.7

16.7

76.6

15.0

85.0

doi:10.1371/journal.pone.0090491.t001
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Figure 2. GG, CC and GC genotypes in the samples. Fig. 2 A, B and C show GG, CC and GC genotype respectively as shown by the results
obtained by RT-PCR.
doi:10.1371/journal.pone.0090491.g002

histological type, pathological grading and clinical stages).
Analyses were conducted by using the computer software SPSS
(version 17.0). P,0.05 was considered the level of statistical
significance.

Discussion
Lipid biosynthesis is essential for the maintenance of cellular
homeostasis while increased de novo lipid synthesis is a common
metabolic feature of carcinogenesis [19]. The increased expression
of FASN and LDLR (Low Density Lipoprotein Receptor) in
tumor cells attest to this statement [20]. SREBPs can regulate
various enzymes involved in fatty-acid and cholesterol biosynthesis. Apart from influencing several enzymes involved in lipogenesis,
SREBP also participates in the conversion of androgen into
estrogen through the aromatization reaction thus raising the level
of estrogen in the circulation. Obesity has also been found
responsible for lowering the levels of progesterone which has a
strong antagonizing effect on the carcinogenic function of estrogen
[21]. Moreover, SREBP1 is also associated with modulating the
transcription of the enzyme 17b-Hydroxysteroid dehydrogenase
type 12 (17 b -HSD12) which is responsible for the transformation
of estrone (E1) to a more potent form, estradiol (E2) [22,23]. So,
we can deduce that SREBP activity is required for tumor growth,
implying that SREBP plays a significant role in oncogenesis. In
addition, the aberrantly increased expression of SREBP-1 has
been found in several cancers, including EC [18].
In this research we postulated that SNPs in SREBF-1gene have
potential role in genetic predisposition of EC. A previous study
detected 19 polymorphisms in SREBF-1 and demonstrated the
association between SREBF-1 polymorphisms and obesity as well
as type II diabetes [19]. Furthermore, epidemiological studies have
confirmed that obesity is one of the major risk factors of EC while
SREBF-1 gene polymorphisms have associations with metabolic
diseases (type2 diabetes and obesity) [24]. Another study
concluded that the SNPs rs2297508 and rs11868035 in the
SREBP-1c gene have relationships with increased risk of T2DM
and dyslipidemia in the Chinese population. The same study also
showed that the SNP (rs11868035) is significantly associated with
insulin resistance (IR) in diabetic patients [25]. However, the
studies, demonstrating the relationship between SREBF-1 genetic
polymorphisms and cancers, are rare. Up till now, only Daniele
Campa and his co-workers have investigated the relationship
between SNPs in SREBF-1 and oncogenesis of breast cancer, but
no statistically significant associations were found between the
SNPs detected and the risk of breast cancer [26]. Thus we have
also further assessed our hypothesis that the genetic polymorphisms are linked with diabetes and obesity along with few other
clinical criteria associated with EC.
To our knowledge, this is the first report examining the role of
SREBF-1 gene polymorphisms in EC. In our study, we found that
the distribution of the SNP (rs2297508) had a distinct demarcation
between EC patients and benign controls. The C allele in the SNP
was associated with higher susceptibility to EC. Therefore, we
predict the high possibility of C allele in the SNP having a crucial
relationship with the risk of EC and we believe that further
exploration would lead researchers towards developing a new
therapeutic target for the treatment of EC.
We further analyzed the association of different clinical
characteristics in EC patients with the SNP. First, we evaluated
association between diabetes and/or obesity and genotypic or
allelic frequency in EC patients. But no statistical significance was
found between the two groups. That is to say, the SNP has the
same distribution in EC patients irrespective of the presence or the
absence of risk factors like diabetes and obesity. It suggested that

Results
SNP identification and genotyping
Our screening identified 10 polymorphisms (SNP1 to SNP10)
including 3 newly detected sites (Fig. 1). The C allele in SNP9
(rs2297508) was detected in eight of thirty patients (26.7%), but in
none of the controls. Other detected SNPs showed little difference
between patients and controls. (Table 1) Then, we selected SNP9
(rs2297508) for further study and analyzed all experimental
samples and controls using real-time polymerase chain reaction.
The results (GG, GC or CC) were analyzed by Step One Software
V2.1. Genotyping was conducted based on the differing amplification curves observed for different genotypes (Fig. 2).

Association between SNP rs2297508 and risk of EC
The allele distribution of SNP (rs2297508) on SREBF-1
genotypes in control groups is consistent with Hardy-Weinberg
equilibrium as tested by x2 test (x2 = 2.27, P = 0.13). The variation
in the distribution of C allele between EC patients and normal
controls was clearly shown (P = 0.027). The x2 test revealed that
the GC/CC genotypes or C allele carriers had an increased risk of
EC (OR = 1.966 and OR = 1.983 respectively) compared to GG
or G carriers respectively. Confidence intervals of the odds ratio
(OR) was used to describe the limitations within which the
estimated calculations should be valid. The comparison of
genotypic and allelic frequencies of the SNP between EC patients
and normal controls is shown in Table 2. The results were
consistent with our preliminary high throughput experiment.

Association between SNP rs2297508 and pathological
grade and the depth of myometrial invasion of EC
We have attempted to explain the role of polymorphic locus
rs2297508 on co-existing conditions like diabetes, obesity, as well
as on different age groups, pathological types and pathological
grades of the cancer, clinical stages and myometrial invasion in EC
patients (Table 3). Since diabetes and obesity are two major risks
known to be closely tied to EC, and the SNP being a crucial
marker of the genetic predisposition of EC, it could be assumed
that there was a potential effect of this particular polymorphism on
the condition. We divided the EC patients into two groups (with
diabetes or obesity and without). However, no significant
difference in allele frequency was evident between the two. Other
criteria for dividing the subjects into various groups were
determined according to previous reports as well as clinical
significance [4,5]. The results showed that the SNP C variant
carriers had higher pathological grade and deeper myometrial
invasion (OR = 2.042 and OR = 2.233 respectively) compared to
G carriers. Furthermore, the GC/CC genotype and the C allele
were significantly associated with pathological grade (x2 = 4.095,
P = 0.043 and x2 = 3.893, P = 0.048 respectively) and myometrial
invasion (x2 = 4.018, P = 0.045 and x2 = 4.170, P = 0.041 respectively). Other criteria such as age, pathological type and clinical
stage did not show any significant association with the SNP.

PLOS ONE | www.plosone.org

5

March 2014 | Volume 9 | Issue 3 | e90491

SREBF-1 SNP and the Risk of Endometrial Cancer

Table 2. Genotype/allele frequency of SREBF-1(rs2297508) in EC patients and normal controls.

SREBF-1

Benign

(rs2297508)

Controls(129)

EC patients(91)

GG

111(86.0%)

69(75.8%)

GC/CC

18(14.0%)

22(24.2%)

G

238(92.25%)

156(85.7%)

C

20(7.75%)

26(14.2%)

x2

P-value

OR

3.748

0.053

1.966

4.867

0.027

1.983

95%CI

1
0.985–3.926

1
1.070–3.676

OR odds ratio Cl confidence limit.
doi:10.1371/journal.pone.0090491.t002

there was abnormal lipid metabolism associated with the SNP in
EC which is independent of diabetes and obesity. Then we
compared age criteria, pathological types and clinical stages, but

no significant associations were obtained, thus providing evidence
that there exists no association between the SNP and those clinical
characteristics. Consistence with the report presented by Li W. et

Table 3. Genotype/allele distribution of SREBF-1(rs2297508) in EC patients with different characteristics.

Endometrial cancer(n = 139)

Diabetes and obesity
condition

Rs2297508
GC/CCa

None

69(75.8%)

22(24.2%)

With one of the two or both

36(75.0%)

12(25.0%)

OR

1.045

95%CI

0.465–2.352

Age (year)

12(27.9%)

.50

74(77.1%)

22(22.9%)

0.914

0.400

0.527

0.768
0.339–1.742
29(24.8%)

Non-endometrioid

17(77.3%)

5(22.7%)

0.042

0.837

0.892
0.303–2.633

26(14.3%)

81(84.4%)

15(15.6%)

19(18.3%)

High grade

20(64.5%)

11(35.5%)

4.095

0.043

2.461

72(83.7%)

14(16.3%)

165(85.9%)

27(14.1%)

198(84.6%)

36(15.4%)

39(88.6%)

5(11.4%)

189(87.5%)

27(12.5%)

48(77.4%)

14(22.6%)

1.012–5.980

0.090

0.232

0.630

0.476

0.490

3.893

0.048

0.995–4.190

75(72.8%)

28(27.2%)

II

14(87.5%)

2(12.5%)

1.584c

III–IV

16(80.0%)

4(20.0%)

0.449d

173(84.0%)

33(16.0%)

0.208c

29(90.6%)

3(9.4%)

0.319c

0.572c

0.503d

35(87.5%)

5(12.5%)

0.007d

0.935d

4.170

0.041

ORc

0.383

95%CIc

0.082–1.792

0.193–2.488

ORd

0.670

0.957

myometrial invasion

0.765

2.042

I

95%CId

P-value

0.260–1.910

85(81.7%)

95%CI

156(85.7%)

x2

0.705

Low grade

OR

Cb

0.417–1.699

88(75.2%)

95%CI

G

0.842

Endometrioid

OR

Clinical Stages

0.012

P-value

0.557–2.215

31(72.1%)

95%CI

Pathological grade

x2

1.111

#50

OR

Pathologic types

Rs2297508

GG

0.693

0.206–2.176

0.336–2.730

,1/2

60(77.9%)

17(22.1%)

$1/2

15(57.7%)

11(42.3%)

4.018

0.045

134(87.0%)

20(13.0%)

39(75.0%)

13(25.0%)

OR

2.588

2.233

95%CI

1.005–6.667

1.020–4.892

Statistical analysis:Pearson x2 test.
Age #50 years old, endometrioid type, low grade, stage I and myometrial invasion ,1/2 were considered as references for comparison.
Odds ratio(OR) of the GC/CC against the GG genotypes.
b
Odds ratio(OR) of the C against the G alleles.
c
Comparison between stage I and II.
d
Comparison between stage I and III–IV.
doi:10.1371/journal.pone.0090491.t003
a
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al. [21], the C allele in the SNP exhibited a significant association
with higher-grade tumor. Moreover, the patients with C allele
showed a higher risk of developing a deeper myometrial invasion
as compared to those with G allele at the SNP locus. This finding
might result from late detection of the disease however we cannot
exclude the possibility of the influence of SNP. There might be a
potential relationship between pathological grade of tumor as well
as depth of myometrial invasion. However further research is
needed to clarify this concept. In summary, the C allele seems to
be a marker for a higher grade tumor and deeper myometrial
invasion in EC, and hence could act as an indispensable marker to
be taken into account in clinical evaluation and treatment of EC in
the near future.
In conclusion, our study mainly investigated the association
between the SNP (rs2297508) in SREBF-1 and the risk of EC and
found that C allele of the SNP is potentially a risk factor for EC. At
the same time, we analyzed the association of the SNP with
different clinical criteria of EC and the results showed that patients
with higher C allelic frequency were more susceptible to develop
high grade tumor and deep myometrial invasion. The results
indicated that the SREBF-1 polymorphism might play an essential
role in increasing the genetic susceptibility to EC. Therefore we
assume that this could assist the physician in clinical diagnosis of
the condition and would also guide towards a targeted clinical
therapy.
In our study, we employed high throughput sequencing, a
reliable technique with great accuracy and precision, to detect 10
SNPs associated with EC including three new ones which might be

of significance for other studies in the future. Furthermore, we
confirmed that the SNP (rs2297508) in SREBF-1 has a significant
influence on EC susceptibility and clinical criteria. However, our
study has some limitations. At the subject level, we don’t have
lifestyle data such as dietary intake, physical activity, hormonal
contraceptive use etc. that are likely to influence the susceptibility
of the SNPs to EC risk. Further, it is unknown whether the SNP
works in coordination with other SNPs in increasing the risk of
EC. Future studies of larger sample size will be necessary to study
the influence of these factors on the association between the SNP
and risk of EC.
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